Analyst Ratings For Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Today, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) stock was downgraded by HC Wainwright from Buy to Neutral.
There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is Hold with a consensus target price of $8.50 per share, a potential 192.10% upside.
Some recent analyst ratings include
- 3/22/2019-Conatus Pharmaceuticals Inc (NASDAQ:CNAT) gets downgraded to Neutral by HC Wainwright
- 3/22/2019-Conatus Pharmaceuticals Inc (NASDAQ:CNAT) gets downgraded to Hold by SunTrust Banks
- 2/13/2019-Conatus Pharmaceuticals Inc (NASDAQ:CNAT) had its Buy rating reiterated by Roth Capital
- 12/6/2018-Conatus Pharmaceuticals Inc (NASDAQ:CNAT) gets downgraded to Hold by Stifel Nicolaus with a price target of $4.00
- 10/6/2017-Conatus Pharmaceuticals Inc (NASDAQ:CNAT) had its Buy rating reiterated by Seaport Global Securities with a $16.00 price target
- On 4/8/2015 Daniel L Kisner, Director, bought 4,000 with an average share price of $5.75 per share and the total transaction amounting to $23,000.00.
- On 7/30/2013 David F Hale, Director, bought 2,588 with an average share price of $11.00 per share and the total transaction amounting to $28,468.00.
- On 7/30/2013 Luke Evnin, Major Shareholder, bought 165,265 with an average share price of $11.00 per share and the total transaction amounting to $1,817,915.00.
- On 7/30/2013 Steven J Mento, CEO, bought 13,800 with an average share price of $11.00 per share and the total transaction amounting to $151,800.00.
About Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company has collaboration agreement with Novartis to conduct three Phase IIb clinical trials Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Recent Trading Activity for Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Shares of Conatus Pharmaceuticals Inc closed the previous trading session at 2,91 +0,030 1,04 % with 2416400 shares trading hands.
